Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 6;21:18. doi: 10.1186/s12935-020-01714-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 5 — Wnt/β-catenin pathway inhibition eliminated the promoting effect of PlGF knockdown on proliferation and glycolysis of PC9 cells. a, b The efficiency of β-catenin knockdown in PC9 cells were detected by Q-PCR and western blot. c After treatment of PlGF overexpression combined with β-catenin knockdown, cell proliferation was measured by CCK-8 assay; PC9 cells are transfected with oePlGF or vector, and then are treated with XAV939, specific inhibitor of Wnt/β-catenin pathway, for 24 h. d Measurement of cell proliferation byCCK-8 assay; e Evaluation of OCR level by cell mito stress test assay; f Evaluation of ECAR level by glycolysis stress test assay; g Detection of PlGF, C-myc, LDHA, and β-catenin by Western blot. *p < 0.05, **p < 0.01 vs. Vector; #p < 0.05, ##p < 0.01, ###p < 0.001 vs. oePlGF + Vehicle. oePlGF represents PlGF overexpression. shβ-catenin represents β-catenin knockdown